PL3811931T3 - Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej - Google Patents

Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej

Info

Publication number
PL3811931T3
PL3811931T3 PL19823228.2T PL19823228T PL3811931T3 PL 3811931 T3 PL3811931 T3 PL 3811931T3 PL 19823228 T PL19823228 T PL 19823228T PL 3811931 T3 PL3811931 T3 PL 3811931T3
Authority
PL
Poland
Prior art keywords
immune checkpoint
checkpoint inhibitor
liposome composition
containing liposome
medication containing
Prior art date
Application number
PL19823228.2T
Other languages
English (en)
Inventor
Susumu Shimoyama
Tadaaki Ioroi
Mikinaga Mori
Tamami Higuchi
Original Assignee
Fujifilm Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corporation filed Critical Fujifilm Corporation
Publication of PL3811931T3 publication Critical patent/PL3811931T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL19823228.2T 2018-06-20 2019-06-20 Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej PL3811931T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018116707 2018-06-20
JP2018211291 2018-11-09
PCT/JP2019/024500 WO2019244979A1 (ja) 2018-06-20 2019-06-20 薬物を内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬

Publications (1)

Publication Number Publication Date
PL3811931T3 true PL3811931T3 (pl) 2024-11-18

Family

ID=68982622

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19823228.2T PL3811931T3 (pl) 2018-06-20 2019-06-20 Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej

Country Status (10)

Country Link
US (1) US12370186B2 (pl)
EP (1) EP3811931B1 (pl)
JP (1) JP7036919B2 (pl)
CN (1) CN112312895B (pl)
DK (1) DK3811931T3 (pl)
ES (1) ES2984148T3 (pl)
FI (1) FI3811931T3 (pl)
PL (1) PL3811931T3 (pl)
TW (1) TWI878230B (pl)
WO (1) WO2019244979A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3603620T3 (fi) 2017-03-31 2025-12-02 Fujifilm Corp Liposomikoostumus ja farmaseuttinen koostumus
WO2020071349A1 (ja) 2018-10-01 2020-04-09 富士フイルム株式会社 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬
US12599557B2 (en) 2019-04-25 2026-04-14 Tlc Biopharmaceuticals, Inc. Liposomal sustained-release compositions containing a therapeutic drug and use thereof
MX2024010261A (es) * 2022-03-31 2024-08-30 Eisai R&D Man Co Ltd Composición de liposomas y composición farmacéutica que contiene liposomas.
JPWO2024111564A1 (pl) 2022-11-21 2024-05-30

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
BR9914601A (pt) 1998-09-16 2001-10-23 Alza Corp Inibidor de topoisomerase capturado por lipossoma
US7244448B2 (en) 2000-06-30 2007-07-17 Tekmira Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
US7102648B1 (en) * 2000-04-11 2006-09-05 Rah Color Technologies Llc Methods and apparatus for calibrating a color display
US20080075762A1 (en) 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20070231379A1 (en) 2002-08-29 2007-10-04 Slater James L Liposome-entrapped topoisomerase inhibitors
US20050129753A1 (en) * 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
US6920642B2 (en) * 2003-12-03 2005-07-26 Bart Dickens Necktie knot simulator
CA2928387A1 (en) * 2004-05-03 2005-11-17 Merrimack Pharmaceuticals, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
US7811602B2 (en) 2004-05-17 2010-10-12 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
ATE401057T1 (de) 2004-10-08 2008-08-15 Alza Corp Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen
US20090285878A1 (en) 2004-11-05 2009-11-19 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
WO2006127962A2 (en) 2005-05-25 2006-11-30 Becton, Dickinson And Comapny Particulate formulations for intradermal delivery of biologically active agents
US20080206139A1 (en) 2006-11-03 2008-08-28 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
CN101485629B (zh) 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
WO2009149150A2 (en) 2008-06-03 2009-12-10 Alza Corporation Composition comprising liposome-entrapped doxorubicin and methods of administration
AR076634A1 (es) 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc Composiciones y metodo para tratar desordenes del sistema nervioso central
ES2593027T3 (es) 2009-03-30 2016-12-05 Eisai R&D Management Co., Ltd. Composición liposomal
US11357728B2 (en) 2009-10-26 2022-06-14 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt
US20130052259A1 (en) 2010-02-01 2013-02-28 Yechezkel Barenholz Liposomes comprising amphipathic drugs and method for their preparation
BR112013016365A2 (pt) 2010-12-27 2018-06-26 Terumo Corp composição de lipossoma e processo para produção do mesmo
EP3069785A1 (en) * 2011-10-25 2016-09-21 The University Of British Columbia Limit size lipid nanoparticles and related methods
CN102764234A (zh) 2012-08-03 2012-11-07 上海现代药物制剂工程研究中心有限公司 一种盐酸拓扑替康靶向脂质体制剂及其制备方法
JP2015534984A (ja) 2012-10-19 2015-12-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 中枢神経系の腫瘍の治療
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
CN104771361B (zh) 2014-01-14 2018-06-01 中国科学院上海药物研究所 一种盐酸拓扑替康脂质体纳米制剂及其制备方法
US10369104B2 (en) 2014-04-01 2019-08-06 Children's Hospital Los Angeles Targeted polymerized nanoparticles for cancer treatment
AU2015327868A1 (en) * 2014-10-03 2017-04-20 Novartis Ag Combination therapies
JP6316182B2 (ja) 2014-12-19 2018-04-25 富士フイルム株式会社 リポソームの製造方法及びリポソーム製造装置
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
WO2017079303A1 (en) * 2015-11-02 2017-05-11 The Cleveland Clinic Foundation Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer
CN111632030B (zh) 2015-11-02 2023-01-17 富士胶片株式会社 包含吉西他滨或其盐的脂质体组合物的制造方法
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
IL303038B2 (en) * 2016-12-05 2024-08-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
EP3560492B1 (en) 2016-12-26 2023-11-29 FUJIFILM Corporation Lipid particle composition and pharmaceutical composition
FI3603620T3 (fi) 2017-03-31 2025-12-02 Fujifilm Corp Liposomikoostumus ja farmaseuttinen koostumus
WO2020071349A1 (ja) 2018-10-01 2020-04-09 富士フイルム株式会社 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬

Also Published As

Publication number Publication date
JPWO2019244979A1 (ja) 2021-06-03
US20210100791A1 (en) 2021-04-08
WO2019244979A1 (ja) 2019-12-26
JP7036919B2 (ja) 2022-03-15
EP3811931A1 (en) 2021-04-28
EP3811931B1 (en) 2024-07-03
FI3811931T3 (fi) 2024-09-12
TWI878230B (zh) 2025-04-01
CN112312895A (zh) 2021-02-02
DK3811931T3 (da) 2024-09-30
CN112312895B (zh) 2023-05-09
US12370186B2 (en) 2025-07-29
ES2984148T3 (es) 2024-10-29
TW202015658A (zh) 2020-05-01
EP3811931A4 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
PL3811931T3 (pl) Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej
ES3063733T3 (en) Pharmaceutical combination comprising tno155 and ribociclib
ZA202000439B (en) Liposome compositions comprising weak acid drugs and uses thereof
PT3603620T (pt) Composição lipossomal e composição farmacêutica
ZA201801747B (en) Medication packaging and dose regimen system
ZA201705591B (en) Medication packaging and dose regimen system
IL281073A (en) History of imidazopyridine and pharmaceutical preparations containing them
GB2578093B (en) Liquid pharmaceutical composition comprising RPL554 and HFA-134A
ZA201800470B (en) An oral pharmaceutical dosage form for the delivery of a peptide and/or protein
EP3275453A4 (en) Pharmaceutical composition containing silybin and ve
EP3330379A4 (en) Aptamer against insulin receptor and pharmaceutical composition containing the same
ZA201905763B (en) Liposomal compositions and solid oral dosage forms comprising the same
IL278517A (en) Azabenzaimidazole compounds and pharmaceutical preparations
IL276311A (en) Methyllactam ring compound and its pharmaceutical use
ZA202106721B (en) Pharmaceutical composition containing antibody against il-5 and use thereof
GB201819957D0 (en) Novel quinazolinone derivatives inhibiting piek and pharmaceutical composition containing same
IL276323A (en) 4-Methyldihydropyrimidinone compounds and their pharmaceutical use
PL3525769T3 (pl) Tabletka ulegająca rozpadowi w jamie ustnej zawierająca burlulipazę i wytworzona z niej kompozycja farmaceutyczna
IL267775A (en) Combined treatment with a Lantrin-1 interfering drug and immune checkpoint inhibitor drugs
PL3811949T3 (pl) Lek kombinowany zawierający kompozycję liposomową z kapsułkowaną gemcytabiną i blokadę punktu kontroli immunologicznej
PL3658122T3 (pl) Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan
EP3347022A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING DUTASTERIDE AND FORMULATION IN CAPSULE COMPRISING SAME
IL276783A (en) The composition and pharmaceutical compound containing it
SG11202000424VA (en) Peptide derivative and pharmaceutical composition containing same
IL291196A (en) Standards and methods for determining the dose of the drug